A carregar...
Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
OBJECTIVES: Type 2 diabetes (T2D) is driven by progressive dysfunction and loss of pancreatic β‐cell mass. Imeglimin is a first‐in‐class novel drug candidate that improves glycaemia and glucose‐stimulated insulin secretion in preclinical models and patients. Given evidence that imeglimin can attenua...
Na minha lista:
| Publicado no: | Endocrinol Diabetes Metab |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8029531/ https://ncbi.nlm.nih.gov/pubmed/33855202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/edm2.193 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|